Cardionovum

Be up
to date.

Latest press release

Cardionovum - first transcontinental China-Europe Webinar on the treatment of complications in arteriovenous access in dialysis patients during COVID-19 pandemic.

Guest from Europe: Prof. Michael Lichtenberg (Germany) & Prof. Matteo Tozzi (Italy).

Video of European guests' speech.

Learn more >>

APERTO OTW® Drug Coated Balloon receives first Chinese NMPA Medical Device Registration Certificate for High Pressure DCB for Vascular Access

APERTO®, our innovative paclitaxel coated balloon for arterio-venous access, has received market approval for China. It is the the first high pressure drug coated balloon available in China to treat obstructive lesions of native Arterio Venous Dialysis Fistulae.

The approval was given based on the statistic results from the solidly designed clinical study in Chinese population:
APERTO AVF RCT CHINA.

Learn more >>

Online Seminar: "CARDIOLOGY CARING in COVID-19 PANDEMICS" China-EU

European Key Opinion Leaders as guests:

  • Prof. Dr. Horst Sievert , Frankfurt, Germany
  • Prof. Dr. Giuseppe Tarantini, Padua, Italy
  • Prof. Dr. Jacques Blacher, Paris, France

Video of European guests' speech.

Learn more >>

RESTORE® Drug-Coated Balloon receives first Chinese FDA medical device registration certificate for two indications

RESTORE®, CARDIONOVUM’s innovative paclitaxel-coated balloon for coronary applications has received market approval for China, making it the first drug-coated balloon (DCB) available in China to treat two indications: in-stent restenosis (ISR) and small vessel disease (SVD). The approval was given based on the impressive results from two solidly designed clinical studies in Chinese populations: RESTORE ISR CHINA and RESTORE SVD CHINA.

Learn more >>

J.C. van den Berg discusses results from the APERTO AVF study

Learn more >>

Koen Deloose discusses final results from the Reflow trial

Learn more >>

Upcoming events

Currently there are no events.

Latest events

Cardionovum® at CSC 2022

Cardionovum® is delighted to announce the release of the XLIMIT Randomized Clinical Trial data.

  • Dr. Luca Testa, the PI of the study, will share his findings on the topic of:
    “    OCT-based analysis of XLIMUS® DES vs. SYNERGY DES”

    Thursday 16th November at 17:45h
    SALA MADRID 1-2

Location:

Hotel Riu Plaza España
Calle Gran Vía, 84,
28013, Madrid, Spain

You are welcome to visit us at booth #2

Date: Nov 16, 2022–Nov 17, 2022

Learn more >>

Cardionovum at GISE 2022

Cardionovum invites you to attend a scientific session:

  • GAP IN KNOWLEDGE:
    Role of drug-coated balloons in de novo lesions

    Dr Alfonso Ielasi - the PI of the Hyper study - will share his findings on the topic of:
    Clinical scenario: “A patient treated with a hybrid DES-DEB strategy”

    Thursday 11st October at 14:30h
    ROOM AMBER 5-6

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano, Italy

You are welcome to visit us at booth #45, 2nd Floor (ALA SUD)

Date: Oct 11, 2022–Oct 15, 2022

Learn more >>

Cardionovum at CIRSE 2022

Cardionovum invites you to visit us at booth #70

Location:

CCIB Conference Center
Plaça de Willy Brandt, 11-14,
08019 Barcelona, Spain
 

Date: Sep 10, 2022–Sep 15, 2022

go top